SI
REGN icon

Sofinnova Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Sofinnova Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,086
Closed -$18.8M – 68
2019
Q4 		$18.8M Buy
+50,086
New +$16.9M 1.36% 16
2018
Q2 		– Sell
-1,304
Closed -$449K – 66
2018
Q1 		$449K Buy
+1,304
New +$454K 0.08% 30

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Sofinnova Investments's REGN Position: Q1 2020 in Review

Sofinnova Investments sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 50,086 shares — an estimated $18.8M sold.

Sofinnova Investments first reported a position in REGN in Q1 2018 and held it in 2 quarters. The position peaked at $18.8M in Q4 2019. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

  • Sofinnova Investments reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Sofinnova Investments sold 50,086 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $18.8M.
  • Sofinnova Investments first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Sofinnova Investments's Regeneron Pharmaceuticals position peaked at $18.8M in Q4 2019.
  • 816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.